MARKET

SYN

SYN

SYNTHETIC
AMEX

Real-time Quotes | Nasdaq Last Sale

0.6500
-0.0151
-2.27%
Opening 13:20 03/03 EST
OPEN
0.6790
PREV CLOSE
0.6651
HIGH
0.6803
LOW
0.6400
VOLUME
6.29M
TURNOVER
--
52 WEEK HIGH
1.700
52 WEEK LOW
0.2522
MARKET CAP
68.40M
P/E (TTM)
-0.9200
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Synthetic Genomics Receives Notice Of Allowance For U.S. Patent Titled 'Recombinant Algal Microorganisms Having Increased Lipid Production, and Methods of Making and Using the Same'
https://patentcenter.uspto.gov/#!/applications/16518360
Benzinga · 2d ago
The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings
Biotech stocks extended their losses in the week ended Feb. 26 amid continued weakness in the broader market. Earnings came in thick and fast, with a skew of small and midcap companies releasing their quarterly results.
Benzinga · 4d ago
Worldwide Irritable Bowel Syndrome with Constipation Drugs Industry to 2028 - Rising Prevalence of Gastrointestinal Disorders Will Significantly Increase the Demand
Dublin, Feb 26, 2021 (GLOBE NEWSWIRE via COMTEX) -- Dublin, Feb. 26, 2021 (GLOBE NEWSWIRE) -- The "Irritable Bowel Syndrome with Constipation Drugs Market...
GlobeNewswire · 5d ago
Synthetic Biologics to Report 2020 Year End Operational Highlights and Financial Results on March 4, 2021
ROCKVILLE, Md., Feb. 25, 2021 /PRNewswire via COMTEX/ -- ROCKVILLE, Md., Feb. 25, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a...
PR Newswire - PRF · 6d ago
Global Human Microbiome Market Analysis, Revenue, Price, Market Share, Growth Rate, Forecast To 2027
Feb 25, 2021 (Heraldkeepers) -- Global Human Microbiome Market The global human microbiome market is anticipated to show at a CAGR 23.52% over the forecast...
Heraldkeepers · 6d ago
Making A List Of Penny Stocks To Buy This Week? Analysts Like These 5
Feb 24, 2021 (Penny Stocks via COMTEX) -- 5 Penny Stocks To Buy According To These 4 Analysts I know it's the weekend of the Big Game, and you may be...
Penny Stocks · 6d ago
Top Penny Stocks To Buy According To These 3 Analysts
Feb 24, 2021 (Penny Stocks via COMTEX) -- 3 Penny Stocks to Buy With Bullish Analyst Ratings While Covid has helped bring a new focus to biotech penny...
Penny Stocks · 6d ago
Multiple Sclerosis Market Current Trends, Segmentation, Key Players and Analysis
Comserve · 02/23 12:22
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SYN. Analyze the recent business situations of SYNTHETIC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SYN stock price target is 1.250 with a high estimate of 1.250 and a low estimate of 1.250.
EPS
Institutional Holdings
Institutions: 29
Institutional Holdings: 1.75M
% Owned: 1.66%
Shares Outstanding: 105.22M
TypeInstitutionsShares
Increased
3
253.42K
New
2
98.10K
Decreased
6
47.38K
Sold Out
5
523.64K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.66%
Pharmaceuticals & Medical Research
-1.55%
Key Executives
Non-Executive Chairman/Independent Director
Jeffrey Kraws
Chief Executive Officer/Chief Financial Officer/Director
Steven Shallcross
Director
John Monahan
Independent Director
Jeffrey Wolf
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About SYN
Synthetic Biologics, Inc. is a clinical-stage company. The Company is engaged in developing therapeutics designed to treat gastrointestinal (GI) diseases. The Company's lead product candidates in Phase III development are SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, Clostridioides difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and Phase II SYN-010 which reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). The Company also develops SYN-020, an early-stage oral formulation of the enzyme intestinal alkaline phosphatase (IAP) to treat both local GI and systemic diseases.

Webull offers kinds of Synthetic Biologics Inc stock information, including AMEX:SYN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SYN stock methods without spending real money on the virtual paper trading platform.